Applying the ATN scheme in a memory clinic population: The ABIDE project

Research output: Contribution to journalArticle

Standard

Applying the ATN scheme in a memory clinic population : The ABIDE project. / Altomare, Daniele; de Wilde, Arno; Ossenkoppele, Rik; Pelkmans, Wiesje; Bouwman, Femke; Groot, Colin; van Maurik, Ingrid; Zwan, Marissa; Yaqub, Maqsood; Barkhof, Frederik; van Berckel, Bart N.; Teunissen, Charlotte E.; Frisoni, Giovanni B.; Scheltens, Philip; van der Flier, Wiesje M.

In: Neurology, Vol. 93, No. 17, 22.10.2019, p. e1635-e1646.

Research output: Contribution to journalArticle

Harvard

Altomare, D, de Wilde, A, Ossenkoppele, R, Pelkmans, W, Bouwman, F, Groot, C, van Maurik, I, Zwan, M, Yaqub, M, Barkhof, F, van Berckel, BN, Teunissen, CE, Frisoni, GB, Scheltens, P & van der Flier, WM 2019, 'Applying the ATN scheme in a memory clinic population: The ABIDE project', Neurology, vol. 93, no. 17, pp. e1635-e1646. https://doi.org/10.1212/WNL.0000000000008361

APA

Altomare, D., de Wilde, A., Ossenkoppele, R., Pelkmans, W., Bouwman, F., Groot, C., ... van der Flier, W. M. (2019). Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology, 93(17), e1635-e1646. https://doi.org/10.1212/WNL.0000000000008361

CBE

Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM. 2019. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. 93(17):e1635-e1646. https://doi.org/10.1212/WNL.0000000000008361

MLA

Vancouver

Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C et al. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. 2019 Oct 22;93(17):e1635-e1646. https://doi.org/10.1212/WNL.0000000000008361

Author

Altomare, Daniele ; de Wilde, Arno ; Ossenkoppele, Rik ; Pelkmans, Wiesje ; Bouwman, Femke ; Groot, Colin ; van Maurik, Ingrid ; Zwan, Marissa ; Yaqub, Maqsood ; Barkhof, Frederik ; van Berckel, Bart N. ; Teunissen, Charlotte E. ; Frisoni, Giovanni B. ; Scheltens, Philip ; van der Flier, Wiesje M. / Applying the ATN scheme in a memory clinic population : The ABIDE project. In: Neurology. 2019 ; Vol. 93, No. 17. pp. e1635-e1646.

RIS

TY - JOUR

T1 - Applying the ATN scheme in a memory clinic population

T2 - The ABIDE project

AU - Altomare, Daniele

AU - de Wilde, Arno

AU - Ossenkoppele, Rik

AU - Pelkmans, Wiesje

AU - Bouwman, Femke

AU - Groot, Colin

AU - van Maurik, Ingrid

AU - Zwan, Marissa

AU - Yaqub, Maqsood

AU - Barkhof, Frederik

AU - van Berckel, Bart N.

AU - Teunissen, Charlotte E.

AU - Frisoni, Giovanni B.

AU - Scheltens, Philip

AU - van der Flier, Wiesje M.

PY - 2019/10/22

Y1 - 2019/10/22

N2 - OBJECTIVE: To apply the ATN scheme to memory clinic patients, to assess whether it discriminates patient populations with specific features. METHODS: We included 305 memory clinic patients (33% subjective cognitive decline [SCD]: 60 ± 9 years, 61% M; 19% mild cognitive impairment [MCI]: 68 ± 9 years, 68% M; 48% dementia: 66 ± 10 years, 58% M) classified for positivity (±) of amyloid (A) ([18F]Florbetaben PET), tau (T) (CSF p-tau), and neurodegeneration (N) (medial temporal lobe atrophy). We assessed ATN profiles' demographic, clinical, and cognitive features at baseline, and cognitive decline over time. RESULTS: The proportion of A+T+N+ patients increased with syndrome severity (from 1% in SCD to 14% in MCI and 35% in dementia), while the opposite was true for A-T-N- (from 48% to 19% and 6%). Compared to A-T-N-, patients with the Alzheimer disease profiles (A+T+N- and A+T+N+) were older (both p < 0.05) and had a higher prevalence of APOE ε4 (both p < 0.05) and lower Mini-Mental State Examination (MMSE) (both p < 0.05), memory (both p < 0.05), and visuospatial abilities (both p < 0.05) at baseline. Non-Alzheimer profiles A-T-N+ and A-T+N+ showed more severe white matter hyperintensities (both p < 0.05) and worse language performance (both p < 0.05) than A-T-N-. A linear mixed model showed faster decline on MMSE over time in A+T+N- and A+T+N+ (p = 0.059 and p < 0.001 vs A-T-N-), attributable mainly to patients without dementia. CONCLUSIONS: The ATN scheme identified different biomarker profiles with overlapping baseline features and patterns of cognitive decline. The large number of profiles, which may have different implications in patients with vs without dementia, poses a challenge to the application of the ATN scheme.

AB - OBJECTIVE: To apply the ATN scheme to memory clinic patients, to assess whether it discriminates patient populations with specific features. METHODS: We included 305 memory clinic patients (33% subjective cognitive decline [SCD]: 60 ± 9 years, 61% M; 19% mild cognitive impairment [MCI]: 68 ± 9 years, 68% M; 48% dementia: 66 ± 10 years, 58% M) classified for positivity (±) of amyloid (A) ([18F]Florbetaben PET), tau (T) (CSF p-tau), and neurodegeneration (N) (medial temporal lobe atrophy). We assessed ATN profiles' demographic, clinical, and cognitive features at baseline, and cognitive decline over time. RESULTS: The proportion of A+T+N+ patients increased with syndrome severity (from 1% in SCD to 14% in MCI and 35% in dementia), while the opposite was true for A-T-N- (from 48% to 19% and 6%). Compared to A-T-N-, patients with the Alzheimer disease profiles (A+T+N- and A+T+N+) were older (both p < 0.05) and had a higher prevalence of APOE ε4 (both p < 0.05) and lower Mini-Mental State Examination (MMSE) (both p < 0.05), memory (both p < 0.05), and visuospatial abilities (both p < 0.05) at baseline. Non-Alzheimer profiles A-T-N+ and A-T+N+ showed more severe white matter hyperintensities (both p < 0.05) and worse language performance (both p < 0.05) than A-T-N-. A linear mixed model showed faster decline on MMSE over time in A+T+N- and A+T+N+ (p = 0.059 and p < 0.001 vs A-T-N-), attributable mainly to patients without dementia. CONCLUSIONS: The ATN scheme identified different biomarker profiles with overlapping baseline features and patterns of cognitive decline. The large number of profiles, which may have different implications in patients with vs without dementia, poses a challenge to the application of the ATN scheme.

U2 - 10.1212/WNL.0000000000008361

DO - 10.1212/WNL.0000000000008361

M3 - Article

VL - 93

SP - e1635-e1646

JO - Neurology

JF - Neurology

SN - 1526-632X

IS - 17

ER -